Sector News

Sanofi scouts for rare disease buyouts

March 1, 2016
Life sciences

Sanofi made a splash in rare disease R&D when it traded $20 billion for Genzyme in 2011, and now the French drugmaker is on the hunt for deals “up to” that size as acquisitive rival Shire angles to dominate the space.

Speaking to the Financial Times, Genzyme CEO David Meeker said the company is surveying the field of rare disease-focused biotech companies, declining to name names. A months-long slump in valuations has made once-pricey targets suddenly more affordable, but Sanofi isn’t feeling pressure to close an acquisition before a potential turnaround, Meeker said.

Among the mid-size players in rare disease are BioMarin Pharmaceuticals, which commands a market cap of around $13 billion, plus Ionis Pharmaceuticals and Ultragenyx, which are worth roughly $4 billion and $2.5 billion, respectively.

The idea dovetails with Sanofi’s recent statements on how it plans to reverse its slumping growth, as recently appointed CEO Olivier Brandicourt has repeatedly said the company is interested in deals big and small to counteract creeping competition and sluggish sales for its banner products.

And rare diseases could be an ideal field to boost Sanofi’s margins. Orphan drugs like Genzyme’s Cerezyme treat small numbers of patients but command high prices, and insurers have traditionally been willing to shell out for such therapies on the belief that they prevent costlier outcomes for sufferers of rare disease. And Meeker is betting those dynamics are unlikely to change despite the furor over drug pricing in the U.S., arguing that the economics of orphan drugs keep the sector “relatively protected from the discussion.”

Meanwhile, the rare disease-focused Shire has signed a $32 billion merger agreement with Baxalta that the company said will make it the largest player in the space, promising to grow revenue to $20 billion by 2020.

By Damian Garde

Source: Fierce Biotech

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).